Is It Possible to Discontinue Tumor Necrosis Factor Antagonists after Psoriasis Remission?
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Tumor necrosis factor (TNF) antagonists are highly effective treatments for psoriasis. These agents provide the opportunity to improve disease activity and achieve clinical remission. Despite its efficacy, long-term use of biologics is associated with high financial costs and possibly life-threatening adverse events. Recently, there has been an increasing interest in discontinuing TNF antagonists in patients with psoriasis who have achieved a positive clinical response. However, there is a paucity of data and clinical guidelines concerning the cessation TNF antagonists in psoriasis treatment. Several factors, including cost, subsequent treatment efficacy, relative risks, and tolerability, should be considered before the decision is made to discontinue TNF antagonists. Well-designed clinical trials are necessary to identify factors that may trigger disease exacerbation after medication discontinuation in order to recognize the potential disadvantages of discontinuing treatment in patients who are previously successfully managed on TNF antagonists.
Abstract
Tumor necrosis factor (TNF) antagonists are highly effective treatments for psoriasis. These agents provide the opportunity to improve disease activity and achieve clinical remission. Despite its efficacy, long-term use of biologics is associated with high financial costs and possibly life-threatening adverse events. Recently, there has been an increasing interest in discontinuing TNF antagonists in patients with psoriasis who have achieved a positive clinical response. However, there is a paucity of data and clinical guidelines concerning the cessation TNF antagonists in psoriasis treatment. Several factors, including cost, subsequent treatment efficacy, relative risks, and tolerability, should be considered before the decision is made to discontinue TNF antagonists. Well-designed clinical trials are necessary to identify factors that may trigger disease exacerbation after medication discontinuation in order to recognize the potential disadvantages of discontinuing treatment in patients who are previously successfully managed on TNF antagonists.
참고문헌 (35)
- Ramirez-Fort MK, "Continuous versus intermittent therapy for moderate-tosevere psoriasis", Clin Exp Rheumatol, 31(4 Suppl 78), pp.S63~S70 (2013)
- Mrowietz U, "A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis", J Eur Acad Dermatol Venereol, 28, pp.438~453 (2014)
- Kavanaugh A, "Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry", Ann Rheum Dis, 74, pp.1150~1155 (2015)
- Chimenti MS, "Anti-TNFαdiscontinuation in rheumatoid and psoriatic arthritis : is it possible after disease remission", Autoimmun Rev, 10, pp.636~640 (2011)
- Menter A, "A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis", J Am Acad Dermatol, 56, pp.31.e1~31.e15 (2007)
- Reich K, "Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis : results of a randomized, long-term extension trial(RESTORE2)", Br J Dermatol, 168, pp.1325~1334 (2013)
- Brezinski EA, "Off-label biologic regimens in psoriasis : a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy", PLoS One, 7, pp.e33486~ (2012)
- Lee LY, "Anti-infliximab antibodies in inflammatory bowel disease : prevalence, infusion reactions, immunosuppression and response, a metaanalysis", Eur J Gastroenterol Hepatol, 24, pp.1078~1085 (2012)
- Lecluse LL, "Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis", Arch Dermatol, 146, pp.127~132 (2010)
- Kui R, "Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor(TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis", J Dermatol, 43, pp.1018~1023 (2016)
- Gordon KB, "Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy", J Dermatolog Treat, 17, pp.9~17 (2006)
- Moore A, "A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis", J Am Acad Dermatol, 56, pp.598~603 (2007)
- Gelfand JM, "Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept : continuous versus interrupted treatment", Value Health, 11, pp.400~407 (2008)
- Ortonne JP, "Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks : the CRYSTEL study", Expert Rev Dermatol, 3, pp.657~665 (2008)
- Griffiths CE, "Retreatment in patients with psoriasis achieving response with etanercept after relapse due to treatment interruption : results from the CRYSTEL study", J Eur Acad Dermatol Venereol, 29, pp.468~473 (2015)
- Papp K, "Adalimumab for moderate to severe chronic plaque psoriasis : efficacy and safety of retreatment and disease recurrence following withdrawal from therapy", Br J Dermatol, 164, pp.434~441 (2011)
- Papp K, "Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study", J Eur Acad Dermatol Venereol, 27, pp.634~642 (2013)
- Gordon KB, "Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption", J Eur Acad Dermatol Venereol, 29, pp.767~776 (2015)
- Tanaka Y, "Stopping tumour necrosis factor-targeted biological DMARDs in rheumatoid arthritis", Rheumatology (Oxford), 55(suppl 2), pp.ii15~ii22 (2016)
- Smolen JS, "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2016update", Ann Rheum Dis, 76, pp.960~977 (2017)
- Edwards CJ, "Dosing down with biologic therapies: a systematic review and clinicians’ perspective", Rheumatology (Oxford), 56, pp.1847~1856 (2017)
- Felson DT, "American College of Rheumatology", European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials, 2011, pp.63, 573~586
- Singh JA, "2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis", Arthritis Rheumatol, 68, pp.1~26 (2016)
- Atzeni F, "What are the dangers of biological therapy discontinuation or dose reduction strategies when treating rheumatoid arthritis", Expert Rev Clin Pharmacol, 9, pp.1403~1411 (2016)
- Schett G, "Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions", Ann Rheum Dis, 75, pp.1428~1437 (2016)
- Lubrano E, "Can traditional diseasemodifying anti-rheumatic drugs be withdrawn or tapered in psoriatic arthritis?", Clin Exp Rheumatol, 31(4 Suppl 78), pp.S54~S58 (2013)
- Cantini F, "Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs", Rheumatology(Oxford), 47, pp.872~876 (2008)
- Coates LC, "Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data", Arthritis Care Res(Hoboken), 62, pp.965~969 (2010)
- Mease P, "Is reduction or discontinuation of therapy an acceptable possibility in psoriatic arthritis?", Clin Exp Rheumatol, 31(4 Suppl 78), pp.S59~S62 (2013)
- Kane D, "A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience", Rheumatology (Oxford), 42, pp.1460~1468 (2003)
- Saber TP, "Remission in psoriatic arthritis: is it possible and how can it be predicted?", Arthritis Res Ther, 12, pp.R94~ (2010)
- Araujo EG, "High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission", Ann Rheum Dis, 74, pp.655~660 (2015)
- Moverley A, "A feasibility study for a randomised controlled trial of treatment withdrawal in psoriatic arthritis(REmoval of treatment for patients in REmission in psoriatic ArThritis(RETREAT(F))", Clin Rheumatol, 34, pp.1407~1412 (2015)
- Cantini F, "Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis : a long-term follow-up study", Biologics, 6, pp.201~206 (2012)
- Huynh DH, "Persistence of low disease activity after tumor necrosis factor inhibitor withdrawal in patients with psoriatic arthritis", Proceedings of 2014 ACR, 2014, ~